Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Location
7946 IVanhoe Avenue, Suite 201, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 204 % +0.08%
Debt-to-equity 78.7 % +4.56%
Operating Margin -246 % -72.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.54M shares -81.9%
Common Stock, Shares, Outstanding 3.18M shares -77.1%
Entity Public Float 4M USD -13%
Common Stock, Value, Issued 320 USD -76.9%
Weighted Average Number of Shares Outstanding, Basic 2.89M shares +338%
Weighted Average Number of Shares Outstanding, Diluted 2.89M shares +338%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4.49M USD +1.51%
Research and Development Expense 10.6M USD +87%
General and Administrative Expense 4.96M USD -2.44%
Operating Income (Loss) -11M USD -74.9%
Nonoperating Income (Expense) 63K USD -29.7%
Earnings Per Share, Basic -4 USD/shares +94.3%
Earnings Per Share, Diluted -4 USD/shares +94.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.67M USD -59.7%
Other Assets, Current 68.1K USD +279%
Assets, Current 2.93M USD -67.8%
Property, Plant and Equipment, Net 124K USD
Other Assets, Noncurrent 128K USD -56.6%
Assets 3.18M USD -66.1%
Accounts Payable, Current 463K USD -76.4%
Liabilities, Current 2.3M USD -17.7%
Other Liabilities, Noncurrent 1.03K USD
Liabilities 2.3M USD -17.8%
Retained Earnings (Accumulated Deficit) -137M USD -8.71%
Stockholders' Equity Attributable to Parent 1.2M USD -82.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 875K USD -86.7%
Liabilities and Equity 3.18M USD -66.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.71M USD +49.9%
Net Cash Provided by (Used in) Financing Activities 1.26M USD -77.9%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 3.18M shares -77.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -450K USD -120%
Deferred Tax Assets, Valuation Allowance 40.4M USD +5.04%
Deferred Tax Assets, Gross 40.4M USD +5.04%
Depreciation 0 USD
Operating Lease, Liability, Current 2.73K USD -92.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.7M USD +4.36%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 1.83M USD +8.4%
Operating Lease, Payments 20.7K USD -9%
Additional Paid in Capital 138M USD +3.97%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 1.25M USD +83271%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%